Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

Lene Kongsgaard Nielsen*, Claudia Stege, Birgit Lissenberg-Witte, Bronno van der Holt, Ulf-Henrik Mellqvist, Morten Salomo, Gerard Bos, Mark-David Levin, Heleen Visser-Wisselaar, Markus Hansson, Annette van der Velden, Wendy Deenik, Juleon Coenen, Maja Hinge, Saskia Klein, Bea Tanis, Damian Szatkowski, Rolf Brouwer, Matthijs Westerman, Rineke LeysHarm Sinnige, Einar Haukås, Klaas van der Hem, Marc Durian, Peter Gimsing, Niels van de Donk, Pieter Sonneveld, Anders Waage, Niels Abildgaard, Sonja Zweegman

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1650-1659
Number of pages10
JournalHaematologica-the Hematology Journal
Volume105
Issue number6
Early online date12 Sep 2019
DOIs
Publication statusPublished - Jun 2020

Keywords

  • PREDNISONE PLUS THALIDOMIDE
  • ELDERLY-PATIENTS
  • EUROPEAN-ORGANIZATION
  • CLINICAL-TRIALS
  • ADVERSE EVENTS
  • MELPHALAN
  • DEXAMETHASONE
  • TERMINOLOGY
  • CRITERIA
  • QLQ-C30

Cite this

Nielsen, L. K., Stege, C., Lissenberg-Witte, B., van der Holt, B., Mellqvist, U-H., Salomo, M., Bos, G., Levin, M-D., Visser-Wisselaar, H., Hansson, M., van der Velden, A., Deenik, W., Coenen, J., Hinge, M., Klein, S., Tanis, B., Szatkowski, D., Brouwer, R., Westerman, M., ... Zweegman, S. (2020). Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. Haematologica-the Hematology Journal, 105(6), 1650-1659. https://doi.org/10.3324/haematol.2019.222299